Antonio Colecchia
Antonio Colecchia is an expert in Gastroenterology at Policlinico di Modena (Italy). As of September 2026, ScienceLeadR ranks Antonio Colecchia in the top 1% of experts worldwide for Hypertension, Portal. Antonio Colecchia has authored 272 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 7 of them ongoing. SLR score: 1,129 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Hepatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 272
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Nutritional Management of Irritable Bowel Syndrome. PMID 41754216 — irritable bowel syndrome, diet, food, signs and symptoms, therapeutics, sucrose | Nutrients | 2026 | 0 |
| Progression rate of diverticular disease and associated risk factors: results from 5-year longitudinal prospective nationwide diverticular disease registry (REMAD). PMID 41746547 — registries, diverticulitis, internal medicine, diverticular diseases, risk factors | Intern Emerg Med | 2026 | 0 |
| Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT). PMID 41530538 — hepatic veno-occlusive disease, blood, microscopy, electron, scanning transmission, incidence, transplantation, child | Bone Marrow Transplant | 2026 | 0 |
| Neoadjuvant Under-Dilated TIPS: Expanding Surgeries for Extrahepatic Malignancies in Patients With Cirrhosis and CSPH. PMID 41363051 — hypertension, portasystemic shunt, transjugular intrahepatic, heart failure, heart, liver, portasystemic shunt, surgical, hypertension, portal, hepatic encephalopathy, ascites, survival rate | Liver Int | 2026 | 0 |
| Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD. PMID 41192692 — liver diseases, hypertension, non-alcoholic fatty liver disease, venous pressure, liver, hypertension, portal, ascites, liver stiffness | J Hepatol Top journal | 2025 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn s disease 2025-521037-86-00 — safety, crohn disease, maintenance, immune system diseases, immune system | Phase 3 | Recruiting | 2026 |
| An Adaptive Dose Ranging Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis 2023-507853-13-00 — colitis, therapeutics, colitis, ulcerative | Phase 2 | Active not recruiting | 2025 |
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative colitis 2025-521038-27-00 — colitis, safety, maintenance, immune system diseases, immune system, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
| An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn s Disease 2025-521036-11-00 — safety, crohn disease, immune system | Phase 3 | Not yet recruiting | 2026 |
| An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis 2025-521035-37-00 — colitis, safety, immune system diseases, immune system, therapeutics, colitis, ulcerative | Phase 3 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map